

## References

L-190

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Central Nervous System Cancers, Version 1.2016.
2. Esteller M, Garcia-Foncillas J, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. *N Engl J Med.* 2000;343(19):1350-4.
3. Gilbert, MR. Establishing the standard of care for patients with newly diagnosed and recurrent glioblastoma. *Am Soc Clin Oncol Educ Book.* 2012;32:112-7.
4. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. *J Clin Oncol.* 2008;26(25):4189-99.